Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05662020 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv2
  2. Study First Submitted
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune response induced with same conditions in 9-19 age group is non-inferior to 20-26 age group, and if the immune response induced by 9-valent HPV study vaccine administrated with 2-dose schedule in females aged 9-14 years is non-inferior to 3-dose schedule in females aged 20-26 years.
Trial Details
NCT Number NCT05662020
Lead Sponsor Beijing Health Guard Biotechnology, Inc
Collaborators: Yunnan Center for Disease Control and Prevention, Mile City Center for Disease Control and Prevention, Qiubei County Center for Disease Control and Prevention, Yanshan County Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Shanghai Stem Pharmaceutical Development Co., Ltd.
Conditions
(from sponsor)		 Human Papillomavirus Infection
Related terms Anus Neoplasms, Condylomata Acuminata, Papillomavirus Infections, Uterine Cervical Neoplasms, Vaginal Neoplasms, Vulvar Neoplasms
Enrollment 2,750 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov